Systemic levels of estrogens and PGE2 synthesis in relation to postmenopausal breast cancer risk

Cancer Epidemiology Biomarkers and Prevention

Volumn 26, Issue 3, 2017, Pages 383-388

  Kim, Sangmi ^a   Campbell, Jeff ^a   Yoo, Wonsuk ^b   Taylor, Jack A ^c   Sandler, Dale P ^c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b AUGUSTA UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

16 EPIESTRIOL; 16 KETOESTRADIOL; 16ALPHA HYDROXYESTRONE; 17 EPIESTRIOL; 2 HYDROXYESTRADIOL; 2 HYDROXYESTRONE; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE; 3 METHOXYESTRONE; 4 HYDROXYESTRONE; 4 METHOXYESTRADIOL; 4 METHOXYESTRONE; ESTRADIOL; ESTRIOL; ESTROGEN; ESTRONE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG USE; ESTROGEN SYNTHESIS; ESTROGEN URINE LEVEL; FEMALE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN URINE LEVEL; TANDEM MASS SPECTROMETRY; BREAST TUMOR; CASE CONTROL STUDY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; URINE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOMARKERS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; DINOPROSTONE; ESTRADIOL; ESTROGENS; ESTRONE; FEMALE; HUMANS; LINEAR MODELS; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS;

EID: 85014519164     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-16-0556     Document Type: Article

References (41)

1. Ulrich CM, Bigler J, Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: Promise, perils and pharmacogenetics. Nat Rev Cancer 2006;6:130-40.
2. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: Mechanistic, pharmacologic, and clinical issues. JNCI Cancer Spectrum 2002;94:252-66.
3. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10:181-93.
4. Bulun SE, Simpson ER, Berstein LM, Santen RJ. Aromatase expression in women's cancers. Innovative Endocrinology of Cancer. Chicago, IL: Landes Bioscience and Springer Science+Business Media; 2008. p. 112-32.
5. Simpson ER, Brown KA. Obesity and breast cancer: Role of inflammation and aromatase. J Mol Endocrinol 2013;51:T51-9.
6. Kim S, Taylor JA, Milne GL, Sandler DP. Association between urinary prostaglandin E2 metabolite and breast cancer risk: A prospective, case-cohort study of postmenopausal women. Cancer Prev Res 2013;6:511-8.
7. Kim S, Rimando J, Sandler DP. Fruit and vegetable intake and urinary levels of prostaglandin e2 metabolite in postmenopausal women. Nutr Cancer 2015;67:580-6.
8. Xu X, Veenstra TD, Fox SD, Roman JM, Issaq HJ, Falk R, et al. Measuring fifteen endogenous estrogens simultaneously in human urine by high-performance liquid chromatography-mass spectrometry. Anal Chem 2005;77:6646-54.
9. Falk RT, Xu X, Keefer L, Veenstra TD, Ziegler RG. A liquid chromatography-mass spectrometry method for the simultaneous measurement of 15 urinary estrogens and estrogen metabolites: Assay reproducibility and interindividual variability. Cancer Epidemiol Biomark Prev 2008;17: 3411-8.
10. Barlow WE, Ichikawa L, Rosner D, Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 1999;52:1165-72.
11. Anderson J, Gerbing D. Structural equation modelling in practice: A review and recommended two-step approach. Psychological Bulletin 1988;103: 411-23.
12. Hu LBP.Cutoff criteria for fit indexes in covariance structure analysis: Conventional criteria versus new alternatives. Structural Equation Modeling: A Multidisciplinary Journal 1999;6.
13. The endogenous hormones and breast cancer collaborative G. endogenous sex hormones and breast cancer in postmenopausal women: Reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
14. Folkerd EJ, Lonning PE, Dowsett M. Interpreting plasma estrogen levels in breast cancer: Caution needed. J Clin Oncol 2014;32:1396-400.
15. Giese RW. Measurement of endogenous estrogens: Analytical challenges and recent advances. J Chromatogr A 2003;1000:401-12.
16. Fuhrman BJ, Schairer C, Gail MH, Boyd-Morin J, Xu X, Sue LY, et al. Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2012;104:326-39.
17. Falk RT, Brinton LA, Dorgan JF, Fuhrman BJ, Veenstra TD, Xu X, et al. Relationship of serum estrogens and estrogen metabolites to postmenopausal breast cancer risk: A nested case-control study. Breast Cancer Res 2013;15:R34.
18. Dallal CM, Tice JA, Buist DS, Bauer DC, Lacey JV Jr., Cauley JA, et al. Estrogen metabolism and breast cancer risk among postmenopausal women: A case-cohort study within BFIT. Carcinogenesis 2014;35:346-55.
19. Moore SC, Matthews CE, Ou Shu X, Yu K, Gail MH, Xu X, et al. Endogenous estrogens, estrogen metabolites, and breast cancer risk in postmenopausal Chinese women. J Natl Cancer Inst 2016;108.
20. Eliassen AH, Spiegelman D, Xu X, Keefer LK, Veenstra TD, Barbieri RL, et al. Urinary estrogens and estrogen metabolites and subsequent risk of breast cancer among premenopausal women. Cancer Res 2012;72:696-706.
21. Samavat H, Kurzer MS. Estrogen metabolism and breast cancer. Cancer Lett 2015;356:231-43.
22. Rosner W, Hankinson SE, Sluss PM, Vesper HW, Wierman ME. Challenges to the measurement ofestradiol: An endocrine society position statement. J Clin Endocrinol Metab 2013;98:1376-87.
23. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximaltoabreast tumorisstimulatedbyPGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:5739-42.
24. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012;2:356-65.
25. Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissues of cancer-free and breast cancer patients. J Clin Endocrinol Metab 1996;81:3843-9.
26. O'Neill JS, Elton RA, Miller WR. Aromatase activity in adipose tissue from breast quadrants: A link with tumour site. Br Med J 1988;296:741-3.
27. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004;291: 2433-40.
28. Gierach G, Lacey J, Schatzkin A, Leitzmann M, Richesson D, Hollenbeck A, et al. Nonsteroidal anti-inflammatory drugs and breast cancer risk in the national institutes of health-AARP diet and health study. Breast Cancer Res 2008;10:R38.
29. Duggan C, Wang CY, Xiao L, McTiernan A. Aspirin and serum estrogens in postmenopausal women: A randomized controlled clinical trial. Cancer Prev Res 2014;7:906-12.
30. Harris RE, Casto BC, Harris ZM. Cyclooxygenase-2 and the inflammogen-esis of breast cancer. World J Clin Oncol 2014;5:677-92.
31. Timoshenko AV, Chakraborty C, Wagner GF, Lala PK. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 2006;94:1154-63.
32. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention. J Clin Oncol 2005;23:254-66.
33. Kalinski P. Regulation of immune responses by prostaglandin E2. J Immunol 2012;188:21-8.
34. Chen EP, Smyth EM. COX-2 and PGE2-dependent immunomodulation in breast cancer. Prostaglandins Other Lipid Mediat 2011;96:14-20.
35. Cui Y, Shu XO, Gao YT, Cai Q, Ji BT, Li HL, et al. Urinary prostaglandin E2 metabolite and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2014;23:2866-73.
36. Catsburg C, Gunter MJ, Chen C, Cote ML, Kabat GC, Nassir R, et al. Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease. Cancer Res 2014;74:3248-58.
37. Gunter MJ, Wang T, Cushman M, Xue X, Wassertheil-Smoller S, Strickler HD, et al. Circulating adipokines and inflammatory markers and post-menopausal breast cancer risk. J Natl Cancer Inst 2015;107.
38. Davenport JR, Cai Q, Ness RM, Milne G, Zhao Z, Smalley WE, et al. Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk. Mol Carcinog 2016;55:1261-61.
39. Falk RT, Gentzschein E, Stanczyk FZ, Garcia-Closas M, Figueroa JD, Ioffe OB, et al. Sex steroid hormone levels in breast adipose tissue and serum in postmenopausal women. Breast Cancer Res Treat 2012;131:287-94.
40. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58, 209 women with breast cancer and 101, 986 women without the disease. Lancet 2001;358:1389-99.
41. Boyles AL, Harris SF, Rooney AA, Thayer KA. Forest Plot Viewer: a new graphing tool. Epidemiology 2011;22:746-7.